ArriVent Is Second Positive IPO Of 2024 After CG Oncology’s Debut

Cancer Drug Developer Closes Up 11.1%

 
• By Mandy Jackson

ArriVent launched the second biopharma initial public offering of 2024, closing above its IPO price on its first day and grossing $175m – and keeping the financial market mood optimistic.

Skyscrapers Cityscape Downtown View, Boston Skyline Buildings. NIght time. IPO hologram.
The positive performance of the year's first two IPOs may drive future offerings • Source: Shutterstock

More from Financing

More from Business